GlaxoSmithKline PLC's migraine medicine Treximet, Bayer AG's

UNITED STATES - JUNE 18: GlaxoSmithKline PLC's migraine medicine Treximet, Bayer AG's Aleve, a form of naproxen, and the GlaxoSmithKline migraine pill Imitrex sit on display at New London Pharmacy in New York, U.S., on Thursday, June 18, 2009. GlaxoSmithKline is struggling to build sales of its year-old migraine medicine Treximet as doctors and insurers object to the cost, calling the pill no better than the two generic drugs it combines. (Photo by Jb Reed/Bloomberg via Getty Images)
UNITED STATES - JUNE 18: GlaxoSmithKline PLC's migraine medicine Treximet, Bayer AG's Aleve, a form of naproxen, and the GlaxoSmithKline migraine pill Imitrex sit on display at New London Pharmacy in New York, U.S., on Thursday, June 18, 2009. GlaxoSmithKline is struggling to build sales of its year-old migraine medicine Treximet as doctors and insurers object to the cost, calling the pill no better than the two generic drugs it combines. (Photo by Jb Reed/Bloomberg via Getty Images)
GlaxoSmithKline PLC's migraine medicine Treximet, Bayer AG's
ACHETER UNE LICENCE
Comment puis-je utiliser cette image ?
475,00 €
EUR

INFORMATIONS

Restrictions :
Contactez votre agence locale pour toute utilisation commerciale ou promotionnelle.For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloomberg’s prior written consent.
Crédits :
Bloomberg / Contributeur
Editorial - n° :
94949893
Collection :
Bloomberg
Date de création :
18 juin 2009
Date de chargement :
Type de licence :
Infos autorisations :
Autorisation non disponible. Plus d'infos
Source :
Bloomberg
Référence :
pdir0816\SHi_j0006.JPG